Immune checkpoints inhibitors (ICIs) have been a breakthrough, with unique response and
survival patterns compared with chemotherapy for patients with advanced Mismatch Repair …

Following initial success in melanoma and lung tumours, immune checkpoint inhibitors
(ICIs) are now well recognized as a major immunotherapy treatment modality for multiple …

Colorectal cancers (CRCs) with deficient mismatch repair (dMMR) or microsatellite instability-
high (MSI-H) often have sustained responses to immune checkpoint inhibitors (ICIs) …

Simple Summary Microsatellite instability (MSI) is a molecular indicator of defective DNA
mismatch repair (dMMR). MSI/dMMR status is observed in approximately 5% of metastatic …

Over the past decade, immune checkpoint inhibitors (ICI) have proven to be promising
agents in a number of solid tumor malignancies. Pembrolizumab and nivolumab are ICIs …

The introduction of checkpoint inhibitors provided remarkable achievements in several solid
tumors but only 5% of metastatic colorectal cancer (mCRC) patients, ie, those with bearing …

Immune checkpoint inhibitors have reshaped the prognostic of several tumor types,
including metastatic colorectal tumors with microsatellite instability (MSI). However, 90-95 …

Despite the recent advances in the systemic treatment of metastatic colorectal cancer
(mCRC), prognostic outcomes have remained to be poor. Thus, what is needed is an …

With the development of immune checkpoint inhibitors, immunotherapy researchers have
facilitated substantial progress for patients with mismatch repair deficient/microsatellite …

Simple Summary The manuscript reports the most recent literature regarding treatment with
ICIs in mCRC, focusing on dMMR/MSI-H and POLE-mutated tumors, discussing current …